Skip to main content

Fiscal Wizard · Single-issue tearsheet

TEM / Jun 22, 2026 Run #7657

TEM

Tempus AI, Inc.

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.

Composite verdict

F 23.9 / 100
Bearish setup · Reversal 6 drivers · 5 gates blocking
  • Pin Bar
  • Engulfing
  • TRIX Zero-Line
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 31st of 47 in Health Information Services

rescore-sweep
Technical synthesisRegime: volatile downtrend
Bull 0%Evidence: High · 15 signals100% Bear
Momentum Bearish 10Mean-reversion Neutral 45

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -97%

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Mixed

44.9 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
Margin of Safety 0
Revenue Growth (YoY) 100
Free Cash Flow Yield 0
Inventory Turnover 85
P/S Ratio 25

Technicals Bearish

3.0 / 100

Bearish setup leads (Pin Bar, Engulfing, Commodity Channel Index); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Engulfing 15
Pin Bar 16
TRIX Zero-Line 25

Risk Gates

5 blocking 8 caution

5 guards active, 28 signals gated.

Debt-to-Assets Blocking

High debt-to-assets blocks bullish signals — balance-sheet leverage risk.

Debt-to-Equity Blocking

High debt-to-equity blocks bullish signals — leverage risk.

Piotroski F-Score Blocking

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for TEM.